ARTICLE | Product Development
Multiple COVID-19 vaccines still in the running despite missing Warp Speed’s cut
June 6, 2020 2:21 AM UTC
Operation Warp Speed has designated COVID-19 vaccine candidates from five groups as the most likely to produce an effective product, but that doesn’t mean other developers are out of the race.
The U.S. initiative seeks to accelerate COVID-19 countermeasure generation, and will fund and coordinate development and manufacturing for the chosen vaccine developers: Moderna Inc. (NASDAQ:MRNA); Pfizer Inc. (NYSE:PFE) and partner BioNTech SE (NASDAQ:BNTX); AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner University of Oxford; Johnson & Johnson (NYSE:JNJ); and Merck & Co. Inc. (NYSE:MRK)...